health pharma news today obesity drugs glp-1 today A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio World Health Organization recommends GLP-1
Description
Similarly, Firkins et al
Back McLean, BA, Wong, CK, Campbell, JE, et al (2021) 'Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation', Endocrine Reviews , 42/2, 101-32
Pharmacotherapy of weight-loss and obesity with a focus on GLP 1-receptor agonists
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
GLP-1RAs compared to placebo In addition, the pooled results showed that first line use of GLP-1RAs has a significant predisposing effect on diarrhea (OR: 2.18, 95% CI: 1.32, 3.60
